S100A1 Protein for use in Treating and Preventing Infarct Extension
OwnerPatrick MOST, Hugo A. KATUS +1inventors
InventorsPatrick MOST, Hugo A. KATUS, Dorothea KEHR
Life of this patent
Estimating the term…
Abstract
The present invention pertains to an S100A1 protein, a biologically active fragment or variant thereof, to a nucleic acid encoding said S100A1 protein or said biologically active fragment or variant thereof, to a vector comprising said nucleic acid, and to a pharmaceutical composition comprising said protein or biologically active fragment or variant thereof, the nucleic acid and/or the vector, for use in treating and/or preventing infarct extension in a patient in need thereof.
Claims26
An S100A1 protein, a biologically active fragment or variant thereof or a nucleic acid encoding said S100A1 protein or the biologically active fragment or variant thereof for use in treating and/or preventing infarct extension in a patient in need thereof, wherein the fragment or variant has at least 80% sequence identity to SEQ ID NO:1.
A vector comprising a nucleic acid encoding an S100A1 protein or a biologically active fragment or variant thereof having at least 80% sequence identity to SEQ ID NO:
- 1, for use in treating and/or preventing infarct extension in a patient in need thereof.
A pharmaceutical composition comprising
- (i) an S100A1 protein, a biologically active fragment or variant thereof having at least 80% sequence identity to SEQ ID NO:1 or a nucleic acid encoding said S100A1 protein, fragment or variant;
- (ii) a vector comprising a nucleic acid encoding an S100A1 protein or a biologically active fragment or variant thereof having at least 80% sequence identity to SEQ ID NO:
- 1;
- or
- (iii) a pharmaceutically acceptable salt of (i) or (ii),
- for use in treating and/or preventing infarct extension in a patient in need thereof, optionally wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient, carrier, and/or diluent.
Method for treating and/or preventing infarct extension in a patient in need thereof, the method comprising administering to the patient:
- (i) an S100A1 protein, a biologically active fragment or variant thereof, or a nucleic acid encoding said S100A1 protein or said fragment or variant thereof,
- (ii) a vector comprising a nucleic acid encoding an S100A1 protein or a biologically active fragment thereof, or
- (iii) a pharmaceutically acceptable salt of (i) or (ii), wherein the fragment or variant has at least 80% sequence identity to SEQ ID NO:1.
Dependencies are inferred from the claim text.